Showing results (71-80 of 114) with videos related to
Sort By:
Pageof 12
Translational Oncology|September 10, 2018
The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer CellsNaoise C Synnott, Stephen F Madden, Vladimir J N Bykov, et al.International Journal of Cancer|December 21, 2004
Mammaglobin a in breast cancer: existence of multiple molecular formsNeil A O'Brien, Norma O'Donovan, Bríd Ryan, et al.British Journal of Cancer|August 19, 2015
ADAM10: a new player in breast cancer progression?Maeve Mullooly, Patricia M McGowan, Susan A Kennedy, et al.International Journal of Cancer|May 27, 2003
Expression of ADAM-9 mRNA and protein in human breast cancerCaroline O'Shea, Norman McKie, Yvonne Buggy, et al.Expert Opinion on Biological Therapy|January 26, 2007
Breast cancer proteomics: clinical perspectivesThomas Y K Lau, Darran P O'Connor, Donal J Brennan, et al.BMC Cancer|September 7, 2006
CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancerDhafir Al-azawi, Gabrielle Kelly, Eddie Myers, et al.Endocrine-Related Cancer|March 3, 2016
Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cellsFrancesco Caiazza, Alyson Murray, Stephen F Madden, et al.Expert Opinion on Biological Therapy|July 30, 2005
Application of DNA microarray technology in determining breast cancer prognosis and therapeutic responseDonal J Brennan, Sallyann L O'Brien, Ailís Fagan, et al.Cancer Biology & Therapy|June 14, 2013
Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell linesAisling Pierce, Patricia M McGowan, Maura Cotter, et al.Endocrine-Related Cancer|February 19, 2017
Vitamin D receptor as a target for breast cancer therapyAlyson Murray, Stephen F Madden, Naoise C Synnott, et al.Pageof 12